Depression is a real issue. The number of individuals who are depressed is gradually increasing. A worrisome figure is that around 8.9 million US residents suffer from both severe depressive disorder and Treatment-Resistant Depression (TRD). The reason for this figure is not that many patients rejected care, but rather many did not respond to standard treatments and some did not…
Standard antidepressants, usually in conjunction with therapy, benefit many individuals diagnosed with severe depression. Unfortunately, for approximately 30% of these individuals, who have Treatment-Resistant Depression (TRD), these drugs have little or no effect. Treatment-resistant does not imply “no hope;” It’s simply a little more difficult. Innovative, cutting-edge therapies are constantly on the horizon, such as Spravato, a nasal spray that…
There is happy news for those suffering from severe Treatment-Resistant Depression (TRD): Spravato (Esketamine) is a revolutionary medication that can bring relief from depressive episodes within hours. For the very first time in 60 yrs, we have a unique antidepressant treatment. For some patients, Spravato treatment is groundbreaking, allowing them to live a life free of depression. What exactly is…